University of Tennessee Health Science Center

UTHSC Digital Commons
Theses and Dissertations (ETD)

College of Graduate Health Sciences

5-2010

Assessing the Sensitivity of the Canadian Adverse Event
Following Immunization Surveillance System ( CAEFISS)
Mina Tadrous
University of Tennessee Health Science Center

Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Health Services Research Commons, and the International Public Health Commons

Recommended Citation
Tadrous, Mina , "Assessing the Sensitivity of the Canadian Adverse Event Following Immunization
Surveillance System ( CAEFISS)" (2010). Theses and Dissertations (ETD). Paper 262. http://dx.doi.org/
10.21007/etd.cghs.2010.0309.

This Thesis is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC
Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized
administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu.

Assessing the Sensitivity of the Canadian Adverse Event Following Immunization
Surveillance System ( CAEFISS)
Abstract
Background
Background: Vaccines are important to public health, but because of the way they are manufactured, their
mechanism of action, and their indicated population, careful monitoring of their adverse events is
necessary. Canada has a national surveillance system that collects reports on adverse events that may
be associated with vaccine administration. Sensitivity is one of the tools used with surveillance systems
to study the extent and characteristics of reporting of a surveillance system. To date, the sensitivity of the
Canadian system has not been assessed.
Purpose
Purpose: To assess the sensitivity of the Canadian Adverse Event Following Immunization Surveillance
System (CAEFISS).
Methods
Methods: Based on specific adverse events following immunization (AEFI) and vaccines chosen for the
study, a thorough literature search was completed to find the best source which identifies expected rates
of AEFI. Studies used were assessed based on quality and sample size. The expected rates of AEFI, in
combination with public health estimates of vaccine coverage rates, were used to estimate the expected
number of reports. The reports provided the actual number of events used to calculate the sensitivity.
Sensitivity was compared based on year of administration, age group, and type of AEFI.
Results: The overall sensitivity of the CAEFISS varied from 1.0% to 136.6% for various AEFI for the years
1997 to 2008. For influenza the sensitivity was found to be 93.6% and 136.3% for GBS and anaphylaxis
respectively. For DTaP, the rates were found to be 15.0%, 1.0%, and 21.2% for anaphylaxis, HHE, and
seizures respectively, and for MMR the rates were 16.5%, 52.7%, and 12.7% in relation to anaphylaxis,
thrombocytopenia, and seizures respectively.
Conclusions: This is the first assessment of the sensitivity of the CAEFISS, and this study found that the
system has reasonable ability to detect AEFI on a national level. CAEFISS had comparable senstivity to
other vaccine reporting systems. Many of the AEFI had sensitivity values higher than the 5%-10% range
traditionally seen in other passive surveillance systems related to adverse events. The greatest variation
of sensitivity was seen between vaccines. Rarity and timing of the AEFI may also impact the sensitivity.
Variation of sensitivity and the variation found in the sensitivity analysis lend to the further development
and implementations of case definitions for rarer adverse events, especially anaphylaxis. Further research
of other factors that impact reporting is necessary.
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ABSTRACT
Background: Vaccines are important to public health, but because of the way they are
manufactured, their mechanism of action, and their indicated population, careful
monitoring of their adverse events is necessary. Canada has a national surveillance
system that collects reports on adverse events that may be associated with vaccine
administration. Sensitivity is one of the tools used with surveillance systems to study the
extent and characteristics of reporting of a surveillance system. To date, the sensitivity of
the Canadian system has not been assessed.
Purpose: To assess the sensitivity of the Canadian Adverse Event Following
Immunization Surveillance System (CAEFISS).
Methods: Based on specific adverse events following immunization (AEFI) and vaccines
chosen for the study, a thorough literature search was completed to find the best source
which identifies expected rates of AEFI. Studies used were assessed based on quality and
sample size. The expected rates of AEFI, in combination with public health estimates of
vaccine coverage rates, were used to estimate the expected number of reports. The reports
provided the actual number of events used to calculate the sensitivity. Sensitivity was
compared based on year of administration, age group, and type of AEFI.
Results: The overall sensitivity of the CAEFISS varied from 1.0% to 136.6% for various
AEFI for the years 1997 to 2008. For influenza the sensitivity was found to be 93.6% and
136.3% for GBS and anaphylaxis respectively. For DTaP, the rates were found to be
15.0%, 1.0%, and 21.2% for anaphylaxis, HHE, and seizures respectively, and for MMR
the rates were 16.5%, 52.7%, and 12.7% in relation to anaphylaxis, thrombocytopenia,
and seizures respectively.
Conclusions: This is the first assessment of the sensitivity of the CAEFISS, and this
study found that the system has reasonable ability to detect AEFI on a national level.
CAEFISS had comparable senstivity to other vaccine reporting systems. Many of the
AEFI had sensitivity values higher than the 5%-10% range traditionally seen in other
passive surveillance systems related to adverse events. The greatest variation of
sensitivity was seen between vaccines. Rarity and timing of the AEFI may also impact
the sensitivity. Variation of sensitivity and the variation found in the sensitivity analysis
lend to the further development and implementations of case definitions for rarer adverse
events, especially anaphylaxis. Further research of other factors that impact reporting is
necessary.
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CHAPTER 1. INTRODUCTION
1.1 Overview
Vaccines are vital to public health, but because of their method of manufacturing,
mechanism of action, and indicated population careful monitoring of their safety is
important. Canada has a national surveillance system which collects reports on adverse
events temporally associated with vaccine administration. An assessment of the
sensitivity of the system has not been conducted to date. Such an assessment would allow
for a better understanding of the system, identify areas for improvement, and reassure the
public of the merit of such reporting systems. This thesis assesses the overall and annual
sensitivity of the system for specific Adverse Event Following Immunization (AEFI).
1.2 Background
Vaccines are unique medical interventions. They are used for primary prevention of
disease and are administered to healthy (non-diseased) individuals (Ellenberg & Braun
2002). This is in contrast to most medical interventions which correct or treat a condition
of illness. Vaccines are used worldwide, such that every person is recommended to
receive multiple immunizations over his lifetime. The success of vaccines in reducing
morbidity and mortality, globally, cannot be overstated. Their effects on overall life
expectancy have far surpassed those of other medical interventions, especially within the
pediatric population. Vaccines are biologic products with complex mechanisms of action
and manufacturing processes (Grabenstein & Grabenstein 1997; Jacobson 2003; Martin
,Nelson, Hershey, & Engler 2003). Thus, although vaccines are generally safe, like any
medical intervention, vaccines do present risk (Bonhoeffer & Heininger 2007).
Public perception of vaccines is important. For vaccine effectiveness, herd immunity,
defined as immunity in a large proportion of a population to ensure the continued
suppression of disease outbreaks, must be maintained to. Therefore, any perception of
vaccine risk or ineffectiveness may profoundly affect vaccine uptake, effectiveness, and
public health. In some instances, vaccine use has been so effective that it may appear to
the public that the disease has disappeared. This perception of disease eradication by
vaccines has begun to undermine the value of immunization to the public (Fowler et al.
2008; Kimmel, Burns, & Zimmerman 2003; O'Hagan & Rappuoli 2004).
Vaccines are designed to induce an immune response, which is the basis for both harm
and protection. Rare but serious adverse events can occur due to vaccines, but even large
clinical studies that serve as the basis for approval may be underpowered to detect these
events. Vaccine safety can be greatly affected by storage requirements and differences
between lots, which require unique lot-by-lot monitoring (Letourneau, Wells, Walop, &
Duclos 2008; Mansoor 1999). Therefore, because of the importance of vaccines to public
health, unique considerations, and challenges in identifying rare adverse events, postmarketing surveillance for vaccines is essential for public health and safety.
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Surveillance systems are one of the primary methods for post-marketing monitoring.
Current AEFI surveillance systems rely on spontaneous reporting of AEFI, and therefore,
these systems are not intended for the detection of new AEFI. Instead, passive
surveillance systems focus on ongoing safety monitoring of the products. These systems
generate associations between vaccines and adverse events and they cannot prove a cause
and effect relationship. The value and appropriate application of spontaneous vaccine
surveillance systems was exhibited with the Rotashield rotavirus vaccine. A surveillance
system generated concern that Rotashield rotavirus vaccine increased the occurrence of
intussusceptions. However, this increased risk was not confirmed until post-marketing
studies were completed (Niu, Erwin, & Braun 2001; Verstraeten et al. 2001; Zanardi,
Haber, Mootrey, Niu, & Wharton 2001). This approach is in contrast to other public
health surveillance systems in which active surveillance is conducted in order to assess of
the rate of occurrence of specific events (i.e. active surveillance (German 2000)).
Surveillance systems have been an integral tool in assuring vaccine safety, since they are
designed for ongoing collection, analysis, interpretation, and application of data
("Immunization information systems progress--United States, 2006," 2008). These
systems are capable of analyzing long-term trends and changes, but more importantly, are
used for immediate action if a signal of increased risk becomes apparent. Although many
specific attributes of reporting and public health systems have been evaluated, the
analysis of sensitivity of an AEFI reporting system holds importance (German et al.
2001). To establish quality and dependability, the United States Center for Disease
Control (CDC) published guidelines for the analysis of public health reporting and
surveillance systems (German et al. 2001). While these guidelines focus on many aspects
of public health surveillance systems, recommendations for sensitivity analysis are
relevant to AEFI reporting.
CAEFISS was created to serve as a national monitoring system for reporting AEFIs. The
current system allows healthcare professionals, consumers, public health workers, and
vaccine manufacturers to report AEFIs. The CAEFISS objectives are to ensure continued
safety of vaccines in Canada, monitor AEFI, identify any unusual rates of AEFI within
specific vaccines and lots, provide timely information to healthcare providers to help
weigh the risks and benefits of immunizations, and to identify specific areas that may
require further epidemiological evaluations. Currently, the majority of CAEFISS is
spontaneously reported, but a portion of the system is active through the IMPACT
program. IMPACT is an active surveillance program which includes 12 Canadian
hospitals accounting for 90% of all tertiary care pediatric beds in Canada. The
implementation of the IMPACT program has increased awareness of vaccine safety and
created a targeted goal of improving vaccine safety for the pediatric population (Scheifele
& Halperin 2003).
The sensitivity of a surveillance system is calculated as the proportion of events in a
specific population that are actually reported. In lay terms, sensitivity measures the
proportion of actual events that are reported to the system. Sensitivity is important to
maintain the ability to detect changes over time, which is directly related to the
proportion of reports. The need to assess sensitivity has special importance for systems
2

that rely on spontaneous reporting. Although higher sensitivity is indicative of a better
system in applications such as diagnostic tests, the CDC guidelines state that sensitivity
in public health surveillance systems is not directly related to the reporting systems
effectiveness. In public health reporting systems, detecting even with low sensitivity is
especially important. Low sensitivity may indicate a need for improvement and an
inability to respond quickly to reports.
Sensitivity of systems can be improved through changes that allow greater simplicity and
timeliness of reporting. The analysis of the sensitivity of the system can be used to
evaluate the extent of reporting to the system. Consistent analysis of any surveillance
system should be conducted to assure its integrity and assist improvement.
The CDC has performed an analysis of sensitivity of the US Vaccine Adverse Event
Reporting System (VAERS) and continues to do so annually (Rosenthal & Chen 1995;
Zhou et al. 2003). Research of the US Vaccine Surveillance System demonstrated that
sensitivity varies by AEFI (Goodman & Nordin 2006). There are no published data on
the sensitivity of the CAEFISS. Sensitivity indicates how well a surveillance system
functions. By assessing how various factors affect the sensitivity a better understanding
will be gained of how certain issues may cause changes in the extent of reporting. These
data will be useful to determine ways to improve the Canadian system.
1.3 Purpose of Study
The purpose of this study was to assess the sensitivity of the CAEFISS between 1997 and
2008. The study looked at selected vaccines and AEFI based on variation in the indicated
population, severity, and incidence to allow for maximum variation and insight into the
characteristics of the Canadian system.
1.4 Specific Aims and Hypotheses
1.4.1 Specific Aims
There were three specific aims. First, this thesis ascertained the sensitivity of the
CAEFISS. Second, this study assessed the variability of the sensitivity for selected AEFI
over time. This study used the combination of the overall sensitivity and the stability of
the sensitivity over time to better understand the characteristics of the system. Third, this
study compared AEFI in relation to their rarity, timing of occurrence, and patient age as
possible factors affecting sensitivity.
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1.4.2 Hypotheses
Based on past studies of sensitivity related to AEFI surveillance systems, existing
structures of the Canadian system, and changes of vaccine knowledge over time, the
following hypotheses were made:





Rarer AEFI will have higher sensitivity. This hypothesis parallels the works
in assessments of other vaccine adverse event systems and general thoughts
on reporting systems found in the literature (Rosenthal & Chen 1995). The
literature clearly indicates that when an AE is seen more often or known to
have a strong correlation, there is a decreased likelihood of reporting (LopezGonzalez et al. 2009).
AEFI that have a rapid onset will have a higher sensitivity. The sensitivity to
events that have a rapid onset will be higher because the time to onset is
smaller thus the reporters conclude a temporal association of the event.
There will be greater sensitivity for AEFI following vaccines given to
children as opposed to those given to adults. Pediatric vaccinations will have
a higher sensitivity than the adult vaccinations. This hypothesis is based on
two factors: first there is greater awareness and experience with vaccines
among healthcare providers caring for children, and second, the active
surveillance system for adverse events among hospitalized children is
conducted by IMPACT (Scheifele & Halperin 2003).
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CHAPTER 2. LITERATURE REVIEW
2.1 Methodology of Search
A literature review was conducted to locate previous studies addressing the sensitivity of
AEFI surveillance systems. A thorough literature review was conducted using both
MEDLINE and EMBASE databases from January 01, 1980 through the date of May 31,
2009. A search using the keywords “vaccine”, “surveillance systems”, “sensitivity”,
“Canada”, and “adverse events” was conducted and articles pulled for relevance. Also
websites of key organizations (CDC, PHAC, and the World Health Organization (WHO))
were searched for relevant material on the topic. Secondary to both searches, all papers
that were pulled had their references reviewed for possibly relevant articles, and a search
for related articles was also conducted. In addition, a search for MeSH terms was done to
check the results of the keyword search. The articles were included if they had any
relevance related to the assessment of AEFI reporting systems, assessment of reporting
systems, sensitivity assessment of AEFI surveillance systems, or assessment of vaccine
safety. Inclusion of papers was limited to those written in the English language and
studies of humans. All abstracts and relevant papers were pulled for further review to
assess their inclusion and relevance.
2.2 Search Results
The initial Keyword search using “vaccine”, “surveillance systems” , “sensitivity”,
“Canada” , and “adverse events” yielded 0 hits; thus, a search excluding the term
“Canada” was conducted. This secondary and broader search yielded 4 hits with only one
relevant article found: Rosenthal et al. (1995). The search was then expanded utilizing
“vaccine” or “adverse event” AND “sensitivity” AND “surveillance systems”. After
duplicates were eliminated, this third search yielded 20 papers with no newly added
relevant articles. The search was again broadened to include “vaccine” and “surveillance
system” and yielded 173 unique papers, of which 7 were somewhat relevant to AEFI
surveillance systems, 2 looked at sensitivity assessment of the systems, and 1was found
in the previous search (Rosenthal & Chen 1995). These two papers describing sensitivity
assessments are discussed in depth in the next sections of this chapter. Other papers had
relevant information pertaining to AEFI surveillance systems or vaccine safety in general.
To ensure that no articles were missed due to the need to broaden searches and the
obvious lack of publications in this area, all relevant papers had their citations searched in
attempt to identify relevant articles. No further relevant studies were found in the
additional related papers and MeSH term search.
The last portion of the systematic search was the search of the websites of major public
health organizations for information. These official websites, especially those of the CDC
and WHO, yielded relevant information. For example, the CDC website contained
general guidelines for the assessment and maintenance of public health reporting systems
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and, of even greater importance, a discussion of the utilization of sensitivity as an
important assessment tool.
2.3 Assessment of Surveillance Systems
The systematic search only found one study of relevance to the assessment of sensitivity
of a system and one study comparing sensitivities of AEFI surveillance systems. At this
time, there are no published studies evaluating the sensitivity rates of CAEFISS.
Rosenthal et al. (1995) conducted the only major study, which assessed the sensitivity of
the CDC system in the US between the years of 1985 and 1990 for the United States
VAERS. VAERS is the United States’ national vaccine surveillance program cosponsored by the CDC and the FDA (Varricchio et al. 2004). The system is a
spontaneous safety surveillance system used to report any AEFI in the United States
(Iskander, Pool, Zhou, & English-Bullard 2006; Zhou et al. 2003).
Rosenthal et al. (1995) measured sensitivity for a number of selected vaccines and AEFI
pairs. They looked at Oral Polio Vaccine (OPV) - Vaccine Associated Paralytic Polio
(VAPP), MMR-seizures, MMR-thrombocytopenia, MMR-rash, and DTP-HHE and DPTseizures. All vaccines and AEFI pairs selected had a proven causal association, as well
as an estimated frequency of occurrence. The study used evidence from the published
literature to estimate the expected incidence rates of selected AEFI. The number of
vaccines doses administered was estimated using: (1) doses purchased with public sector
funds and (2) numbers of doses distributed by manufacturers less doses returned by
providers (3) the National Health Interview Survey (NHIS) was used for specific
childhood vaccinations coverage rate estimates. Using the AEFI rates from the literature,
in combination with the estimate of the number of doses administered, the expected
number of AEFI occurring was estimated. The number of AEFI reported is divided by
the expected number of AEFI to calculate the sensitivity for each specific AEFI. The
sensitivity was calculated for overall estimates and separately for only publically
administered vaccines. In order for reports to be included as an AEFI they had to meet
specific criteria based on timing and age group of the event in reference to the
administration. The study found a large range in reporting sensitivity related to the rarity
and severity of AEFI. Specifically the sensitivities for reporting poliomyelitis after
administration of OPV was 72% whereas it was less than 1% for rash and
thrombocytopenia after administration of the MMR vaccine. The authors’ discussed the
issues related to the underreporting of new and rare AEFI, inadequate information
reported, and effects of publicity on reporting rates. The authors went to state that
sensitivity may also be associated with clinical severity, temporal proximity to
vaccination, and healthcare workers’ obligations to report particular AEFI. The authors
also discussed the need for case-definition that would allow reports to be more efficiently
decoded and assessed. Currently the CDC completes the same style analysis annually
but does not publish their results.
McNeil et al. (2007) compared the sensitivity of the VAERS system to that of the
independently operated US military AEFI Surveillance system. The outcome was used to
6

assess the agreement between two systems utilizing a sensitivity value, in which the
number of VAERS reports was considered the denominator compared to the number of
matching reports in the military system. The analysis was completed with all anthrax
related AEFI reports as well as all vaccine reports. The sensitivity of the anthrax only was
found to be 74% and 73% for all vaccines. In other words, the military AEFI surveillance
system picked up on 74% and 73% of reports that were also reported to the VAERS.
Although the systems are interconnected, the study showed the dynamic nature of many
of these AEFI surveillance systems. Moreover, it serves as another example of
differences in sensitivity rates based on AEFI, although they referred to the exact same
events between systems.
2.4 Assessing Sensitivity of Surveillance System
The CDC published a guideline for the analysis of public health reporting system and
surveillance systems (German et al. 2001). This guideline applies to all surveillance
systems; it discusses many important characteristics that need to be assessed in any
system to ensure its quality and dependability of reporting. One of the major factors listed
as necessary for assessment of any system is that of sensitivity. The need to assess
sensitivity is highly emphasized in the guidelines, especially in systems in which passive
reporting is utilized. Low sensitivity may indicate a need for improvement and a lack of
ability to respond on time to the reports. The guidelines do add an important note that
sensitivity is not directly proportional to how well the system is working. Higher
sensitivity of one system may not be equivalent to concluding that one system is
performing better than another system.
Even more important than a higher sensitivity is having sensitivity that is high enough to
detect changes coupled with stability of the value over time. Sensitivity of systems can
be improved through changes that will allow for greater simplicity and timeliness of
reporting. The guidelines describe sensitivity as the number of reports collected, divided
by the number of reports expected in a specific population under surveillance. The report
further emphasizes the need for comparison to literature for expected rates. This parallels
the way that sensitivity was analyzed in the Rosenthal et al. (1995) study and this study.
The guidelines discuses how improvement in sensitivity over time can indicate increased
awareness, improvements in technology, or can show artifacts necessary for assessment.
The guidelines continually state the importance of continuous analysis of any system in
place in order to assure its integrity and continuous improvement (German et al. 2001).
2.5 Assessment of Drug Adverse Event Reporting Systems
A separate search was conducted for relevant literature related to the assessment of
spontaneous AE surveillance systems related to drugs. Literature in this area was much
broader than that found related to vaccine topics. There was a separate MeSH term
specific for adverse drug reaction surveillance systems but when combined with
7

measures of sensitivity there was still a small number of published articles. A further
keyword search and related articles search was also conducted to ensure the search was
thorough and extensive in nature. The majority of the literature utilizing sensitivity was
found to be related to the assessment of hospital or smaller specific systems rather than
national or regional systems. A great deal of the recent published literature is related to
the creation of signal detection models and applications of various techniques and
systems of detection (Handler et al. 2008; Jhung et al. 2007; Koh & Li 2005; Majdzadeh
& Pourmalek 2008; Nebeker et al. 2007; Visweswaran, Hanbury, Saul, & Cooper 2003).
To further ensure the results from the search were valid, the FDA information service
was contacted and the question submitted and there was no internal data or published
reports made available related to sensitivity or other sorts of published assessments.
In the studies of smaller systems, the sensitivity is calculated by examining the ratio of
the actual number of reports to the true number of events using a gold standard
(presumably active) method of surveillance (Betancourt, Hakre, Polyak, & Pavlin 2007).
For example, in a paper published by Hwang et al. (2008) looking at a computer-based
adverse event monitoring system, the number of reports picked up by the system was the
actual number (numerator) and the number of reports picked up by a pharmacist
assessment of the records is noted as the expected (denominator). These two values were
then calculated to estimate the sensitivity of their system (Hwang, Lee, Koo, & Kim
2008). The sensitivity of this computer detection system was found to be 79%.
Few studies had a national level assessment of sensitivity. Studies looking at regional and
national reporting in Europe have concluded that the reporting rates would remain around
5% for all adverse drug reactions nationally (Begaud, Martin, Haramburu, & Moore
2002). In a study published by McAdams et al. in 2007, the extent of reporting to the
FDA adverse event reporting system was estimated for rhabdomyolsis related to statin
use (McAdams, Staffa, & Dal Pan 2008). Their study utilized cohort incidence rate
estimates, national distribution estimates of statins, and average day supplies to estimate
the number of US statin-associated cases of hospitalized rhabdomyolsis. This ‘expected’
value was then compared to the observed number of reported cases. This value was
referred to as the estimated extent of reporting and was reported separately for every type
of statin. This value is calculated similarly to sensitivity but was not referred to as such.
The study found that the extent of reporting varied from 5% to 31.2% for specific statins.
The authors were able to document surveillance system responsiveness to targeted efforts
to improve reporting sensitivity. Specifically a mass campaign using “Dear Healthcare
Provider” letters led to increased reporting for cerivastatin from 14.8% to 35.0%.
2.6 Summary
Sensitivity has been cited as a useful mechanism of assessing reporting to surveillance
systems in much of the literature as well as the CDC guidelines. Despite this noted
importance of the assessment of sensitivity, the literature shows a gap in assessments of
both drug and AEFI national surveillance systems. Only one study evaluating a national
AEFI surveillance system has been published, and was published in 1995. More
8

specifically, there is no published work assessing the sensitivity of CAEFISS. Thus this
study is unique in that it provides information on the sensitivity of the CAEFISS. The
analysis of sensitivity of these systems is helpful in filling an identified gap in the
literature and gaining a better understanding of the characteristics of the system in hopes
for future improvements.
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CHAPTER 3. METHODS
3.1 Overview of Methods
The methodology used to complete this study can be broken into various steps (Figure
3.1). Each is essential for creating the model used to estimate the values needed to
calculate and assess the sensitivity. The model was used to assess which characteristics of
the system affect the extent of reporting. The model used to calculate the expected
number of AEFI comprises: the published rates of selected AEFI based on proven causal
associations, the estimated number of vaccines administered and the calculated expected
number of events. Sensitivity was then calculated based on the ratio of observed to
expected AEFI reports.
Each of these values can be broken into separate steps and used in the final model and
calculations of the sensitivity. The overall sensitivity was calculated for the total study
time period, from 1997 through 2008 as well as yearly values within that time range. All
of the variables used in the model and calculation were analyzed utilizing Excel.
A descriptive analysis looking at the number of reports in total meeting the criteria as
well as by professional affiliation, AEFI type, age groups, and year was conducted and
reported. This descriptive analysis gave us an understanding of the variation in the
quantity of reports received.
Overall, the selection of the vaccines and their associated AEFI was conducted in a
manner that allowed for the greatest variation in age group indication, timing of AEFI,
and seriousness related to the AEFI selected. Selection of vaccines and AEFI were based
upon the following criteria (Table 3.1):
1)

A known correlation between the vaccine and the AEFI.
All of the selected AEFI have been accepted with certainty in the literature to be
associated with the specific vaccine. Evidence for correlation was drawn from
CDC MMWR Reports, Institute of Medicine (IOM) reports, and past sensitivity
studies (Fiore et al. 2009; Rosenthal & Chen 1995; Stratton et al. 2001).

2)

Vaccines routinely administered and recommended to large proportions of the
Canadian population.
Newer vaccines (within the last 10 years) and travel vaccines were not included in
this study. It is important to note that although newer vaccines were not included
some vaccine types may have had newer product lines or changes in formulation
during the indicated time period of this study. These were included.
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Step 1
Step 2
Step 3
Step 4
Step 5
Step 6

Based on the AEFI and vaccines chosen, a thorough literature search was
conducted to find the expected rates of AEFI.
PHAC and WHO statistics and survey estimates were used to estimate the
coverage rates of all vaccines in question over the years of the study.
Census Data was used to estimate population sizes.
Based on the values developed in Steps 1 -3 a model was created to calculate
the expected number of AEFI.
Sensitivity was calculated per year and overall. Sensitivity was trended over
years in question.
One-way and two-way sensitivity analysis of the sensitivity value was
conducted.

Figure 3.1 Step-wise Approach to Analysis
Notes: These steps are discussed in full detail in their respective sections in this chapter.
PHAC is used to indicate current as well as former activities when the agency was still
part of Health Canada. AEFI=Adverse Event Following Immunization; PHAC=Public
Health Agency of Canada; WHO=World Health Organization.
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Table 3.1 Vaccines and AEFI to be Analyzed by Temporal Association of AEFI
Timing of AEFI
Vaccine

Minutes to Hours

Influenza

Anaphylaxis

DtaP

Anaphylaxis

MMR

Anaphylaxis

Days

Weeks
GBS

HHE
Seizures
Thrombocytopenia
Seizures

DTaP=Diphtheria Tetanus and Acellular Pertussis Vaccine; MMR=Measles, Mumps, and
Rubella Vaccine; HHE=Hypotonic-Hyporesponsive Episode; GBS=Guillan-Barre
Syndrome
3)

Analysis of vaccine and AEFI in previous evaluations of surveillance systems
(some but not all selected met this criterion) (Rosenthal & Chen 1995).
These AEFI include seizures, HHE, and thrombocytopenia. Anaphylaxis and GBS
were not analyzed in the previous related study.

4)

Vaccines used in a variety of age groups.
MMR and DTaP are routinely administered to infants and children versus
influenza vaccination which was only analyzed for adults.

5)

Variation in timing of AEFI.
Events occurring within hours of vaccine administration include anaphylaxis.
Those occurring within days are HHE, severe site reactions, and seizures
associated with DTaP those within weeks are GBS associated with influenza
vaccination, thrombocytopenia and seizures associated with MMR vaccination.
3.2 Estimating Expected Rates of AEFI

In order to derive the expected rates for the AEFI, a systematic literature review was
performed using MEDLINE. A search was completed for each vaccine, as well as the
AEFI of interest (Table 3.1). A keyword search using the name of the vaccine and the
AEFI was conducted. Only English language and human studies were included. Studies
retrieved included guidelines, clinical trials, and large epidemiological studies as well as
accepted tertiary resources related to AEFI. Acceptable tertiary resources included
textbooks and organizational guidelines. All publications used had their citations
searched for further relevant literature. When there was clear discordance in published
rates efforts were made to select the estimate from the most methodologically sound
12

study based on design, power and when it was performed. For each vaccine and AEFI,
these published and selected expected rate values were used in the model as the expected
incidence of the AEFI.
3.3 Estimating Expected Number of AEFI
The next step was to determine the estimated doses of vaccines administered within a
time period. This number can only be estimated because Canada does not currently have
a national vaccine registry. An estimated value was derived from the following pieces of
information: the number of individuals within an age group indicated to receive the
vaccine and the coverage rates for that specific vaccine.
3.3.1 Population Statistics
The first component used in the estimates is the population eligible for immunization for
a specific vaccine. All population statistics were drawn from Statistics Canada
(CANSIM) utilizing the E-STAT online interface (CANSIM : summary directory 2001).
Population census data was drawn for every year between 1997-2008 by year and age
group. Each vaccine had its indicated population calculated per year. The indicated
population can vary per year as the recommendations made by the PHAC change over the
years (Canadian immunization guide : user survey : final report 2005). For each year
research was done by looking at releases of the Canadian Communicable Disease Report
(CCDR) to see if any variations occurred in the age indications of specific vaccines. For
the purposes of this study, the annual population for influenza vaccine was all individuals
12 years of age and older. For DTaP, the population comprised children in their first few
years of life for the 5 injection series. This is the same population as evaluated for the
two injection series for MMR.
3.3.2 Coverage Rates
The coverage rate for a vaccine is the proportion of the indicated population who actually
received the vaccine in the specified time period. This information can be drawn from
published coverage statistics and health surveys conducted by the WHO and PHAC. The
WHO/UNICEF review of national immunization coverage is up-dated yearly and reviews
many countries immunization rates for various vaccines. For Canada the reports used
independent surveys conducted by both UNICEF and the WHO, as well as national
surveys conducted by organizations within Canada. The report contains coverage rates
for the first DTaP and third DTaP vaccinations from 1987 through to 2008.
For the influenza vaccination coverage rate, the Canadian Community Health Survey
(CCHS) was utilized. CCHS is a national health survey conducted every 2-3 years to
collect information related to health status, health care utilization, and health
determinants of the Canadian population (Beland 2002). Although the survey is designed
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to cover an array of topics related to healthcare, a portion of the survey is used to estimate
the influenza vaccination rates for those aged 12 years and above. For intervening years
when data were not collected an extrapolated trend value was used to fill the gaps. For
example, for 1997, the rate found in the survey was 15% and in 2000 the survey found a
rate of 27%. That suggests there was an increase of 12% over a 3 year period. This value
was then averaged over the 3 years allowing for an annual increase of 4% in the rate, so
that the rate was 19% and 23% for 1998 and 1999 respectively.
Lastly, the National Immunization Coverage Survey, which is conducted biannually by
PHAC, was used to attain coverage rates. This survey is mailed out nationally to assess
immunization coverage rates for 2 and 7 year olds. The survey contains information for
four injections of DTaP and the first injection of MMR in those 2 years and younger. It
also contains coverage rates of 5 injections of DTaP and 2 injections with MMR for 7
year olds. The survey also contains data regarding the median timing of administration
within a window of time. All three data sources were used to determine the best estimate
per year of the coverage within the specific indicated population. The resources used for
these estimates come from nationally and internationally, credible and non-biased
resources. The resources have been used in many published works.
3.3.3 Estimating Doses Administered and Expected Number of Events
Using the per year specific estimates of the indicated population and the year-specific
estimated coverage rates, the two values were multiplied to calculate the estimated
number of doses administered for a year (Equation 3.1). This value was then calculated
for each year between 1997 and 2008. The total number of doses administered in that
time period was also totaled in order to calculate the total number of doses given in the
time period of interest. This value was then used to estimate the total number of events
expected (Equation 3.2).
Equation 3.1 Calculation of Estimated Number of Doses Administered:
Estimated Number of Doses Administered (Nev) / Year = Coverage Rate in specific Year
(Cr) * Population Indicated (Ni)
Equation 3.2 Calculation of Estimated Number of Events:
Estimated Number of Events/Year (Ned) = Estimated Number of Doses Administered (Nd)
* Event Rate (Ni)
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3.4 Number of Events and Calculating Sensitivity
The number of reports was drawn from the CAFISS database. This database has a record
of each AEFI reported to the government from consumers, public health, and healthcare
providers. All events reported between 1997-2008 were used. The data had no patient
identifying information. Specific data obtained for this study was the year vaccine was
administered, type of vaccine(s) administered, type of AEFI, age group, and reporter
professional affiliation.
The sensitivity value for each AEFI specific for each vaccine was calculated by dividing
the number of actual reports by the expected number of reports (Equation 3.3). This
value was calculated for each year and overall for the time period in question. The
sensitivity trend for each AEFI was compared over time to assess for stability over time.
Any reports related to the whole-cell pertussis vaccines and all data from 1997 were
excluded to ensure that this transition year did not affect the DTaP sensitivity.
Equation 3.3 Sensitivity Calculation:
Sensitivity (S) = Number of Actual reports (Na)/ Number of Expected Reports (Ne) *100%
3.5 Sensitivity Analysis
All values used and assumptions of any model are subject to variation and the possibility
of error. A sensitivity analysis was used to assess the impact of variations in the
assumptions used in the calculations. The first one-way sensitivity was conducted by
varying the expected rates used in the model by +/- 5%. A one-way sensitivity analysis
was also conducted for the coverage rates assuming a +/- 5% variance. The two-way
analysis was a combination of the one-way analyses in which the variation of the
coverage rates and the expected rates of AEFI were investigated simultaneously. This
resulted in 4 two-way analyses.
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CHAPTER 4. RESULTS
4.1 Expected Rates of AEFI
Utilizing a through literature review as described in the previous chapter, the expected
rates of AEFI and the vaccines of interest were found (Table 4.1). All rates of AEFI rates
are reported as the number of cases per number of doses administered. Some AEFI such
as GBS with influenza, HHE with DTaP, seizures with MMR and DTaP, and
thrombocytopenia with DTaP have known rates that are well documented in the literature
and there is a general consensus behind their rates of occurrence. Anaphylaxis with
influenza and MMR had rates that greatly varied from each other. Rates were selected
from the largest, best-designed studies.
4.1.1 Influenza
Influenza vaccination adverse event rates were inconsistent. Anaphylaxis was analyzed
for influenza as well as the other two vaccines of interest. Two relevant articles for the
rate of anaphylaxis with influenza vaccine were found. One study was a review article
(Zent 2002) discussing the possible causes for anaphylaxis and the rate of 0.65 cases per
million doses was concluded. The articles go on to state that in general the rate would be
around 1 case per million doses administered. The data used was drawn from a VAERS
system. The second study was that of Bohlke et al. (2004) which utilized data from
HMOs for the pediatric population. They did not report any anaphylaxis cases related to
influenza with 197,964 doses administered. They estimated the general risk with any
anaphylaxis within the pediatric population was around 0.65 cases per million doses
administered. This rate was derived from a general risk of anaphylaxis with any
vaccination for the pediatric population. The rate of 1 case per million was selected due
to its general consensus in textbooks and review articles for any vaccination (Bohlke et
al. 2003; Grabenstein & Grabenstein 1997; Nokleby 2006). For GBS all studies were in
agreement that there is 1 excess case per million doses (Babl, Lewena, & Brown 2006;
Bonhoeffer, Heininger et al. 2004; Juurlink et al. 2006; Lasky et al. 1998; Souayah,
Nasar, Suri, & Qureshi 2007).
4.1.2 DTaP
For DTaP, three separate AEFI were assessed. For anaphylaxis the rate with DTaP
vaccination was found to be 8.6 cases per million doses (Bohlke et al. 2003). For HHE
the accepted rate of occurrence was reported as 140 cases per 140,000 with the acellular
pertussis containing vaccine (Babl et al. 2006; Bonhoeffer et al. 2004; Braun et al. 1998;
DuVernoy & Braun 2000). A rate of 0.22 cases of seizure per 1000 doses with DTaP
vaccination was selected (Chen, Mootrey, & DeStefano 2000; Le Saux et al. 2003).
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Table 4.1 Expected Rates of AEFI Based on Literature
Vaccine

AE

Influenza

Anaphylaxis
GBS

DTaP

Anaphylaxis
HHE
Seizures

MMR

Anaphylaxis
Thrombocytopenia
(ITP)
Seizures

Rates per
Doses
Administered
1 case per
million
1 case per
million
8.6 cases per
million
140 cases per
100,000
0.22 cases per
1000
14.4 per
million
1 case in
30,000-40,000
1case per 1000
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Type of Study/Reason
Review article/consensus
Consensus
Review/Epidemiological
Consensus- Epidemiological
Consensus-RCT
Epidemiological
Consensus- Epidemiological
Consensus-RCT

4.1.3 MMR
Three AEFI for MMR were assessed. For anaphylaxis, the literature was found to have
varying rates. The rate used was 14.4 cases per million doses administered. The rate
selected was from a large epidemiological study mentioned above that utilized large
HMO data sets to assess the incidence of anaphylaxis (Bohlke et al. 2003). This large
dataset has been utilized in prior studies for the vaccine safety datalink and contains
approximately 6 million persons worth of data (Chen, DeStefano et al. 2000). Other
reported rates, that were not selected, were calculated utilizing surveillance systems. Due
to their intrinsic limitation, these systems were not well suited to capture the incidence
within a population (Babl, Lewena, & Brown 2006). One study utilized measure of IgE
antibody to attempt to quantify the rate of anaphylaxis (Pool et al. 2002). The study found
a rate closer to the concluded rate from the Bohkle et al. (2003) study which was
substantially higher that the rates drawn from surveillance systems.
The other two AEFI were thrombocytopenia and seizures both of which have consensus
rates that are drawn from both RCTs and epidemiological studies (Babl et al. 2006;
Grabenstein & Grabenstein 1997; Miller et al. 2001; Stowe, Kafatos, Andrews, & Miller
2008; Stratton, Howe, Johnston Jr, & Majewski 1994). Thrombocytopenia had a rate of 1
case per 30,000 doses administered and seizures had a rate of 1 case per 1000 doses
administered.
4.2 Estimated Number of Vaccines Administered
4.2.1 Coverage Rates
The estimated number of vaccine doses administered was calculated from the coverage
rates (Table 4.2) and the size of the indicated population. It was evident that in both the
DTaP and MMR series coverage rates decreased further into the series. DTaP coverage
dropped from an estimate of 97-98% for the first dose to 85-94% for the third and 68%
for the 5th dose in the series. MMR had the same trend of a 96% coverage rate for the first
injection in the series throughout most years with a drop to 74% for the second injection.
Influenza vaccination over the years had a general upwards trend in the coverage rate
with only 15% in 1997 and reaching 34% in 2005-2008 (Figure 4.1).
4.2.2 Targeted Population and Estimated Doses Administered
The second value important to the computation of the number of doses administered is
that of the size of the indicated population (Table 4.3). There were a total of 42,091,244
doses of DTaP, 12,708,045 doses of MMR, and 90,779,438 doses of influenza vaccines
estimated to have been administered between the years of 1997-2008. The table below
depicts the numbers attributed to each year as well as the number of individuals who
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Table 4.2 Coverage Rates by Source and Year
Vaccine

Data Source

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

Influenza

Canadian
Community
Health Survey

15%

19%*

23%*

27%

27%*

28%*

28%

31%*

34%

34%*

34%* 34%*

DTaP

WHO Estimate
- DTP 1 Dose

98%

98%

97%

97%

97%

97%

97%

97%

97%

97%

97%

97%

CHS Estimates
– DTP 2 Dose

92%

94%

96%

94%

94%

95%

94%

96%

96%

96%

96%

96%

WHO Estimate
- DTP 3 Dose

86%

90%

94%

91%

91%

93%

91%

94%

94%

94%

94%

94%

75%

75%

75%

75%

75%

75%

75%

75%

75%

75%

75%

75%

68%

68%

68%

68%

68%

68%

68%

68%

68%

68%

68%

68%

96%

96%

96%

96%

96%

96%

96%

96%

96%

96%

96%

96%

74%

74%

74%

74%

74%

74%

74%

74%

74%

74%

74%

74%

MMR

CHS 7 year
olds Injection 4
(2002)
CHS -7 year
olds Injection 5
(2002)
CHS 7 year
olds Injection 1
(2002)
CHS -7 year
olds Injection 2
(2002)

2008

Notes: * These values for influenza are extrapolations and no value was available for this year. All values found in multiple
sources did not vary by more than 2% in coverage rate. Rates of influenza are based on the total population aged 12 and older.
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Figure 4.1 Estimated Canadian National Immunization Coverage Rates for Influenza, DTaP, and MMR from 1997-2008
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Table 4.3 Indicated Population and Total Doses per Year from 1997-2008
Influenza

DTaP

MMR

Indicated
Population

Doses
Administered

Doses
Administered

Year

Seasonal
Injection

Total

Injections
1-3

4th
Injection

5th
Injection

Total

Total

1st
Injection

2nd Injection

Total

Total

1997

25,146,615

3,771,992

1,069,785

381,771

408,589

1,860,145

1,548,371

381,771

387,807

769,578

653,478

1998

25,427,796

4,831,281

1,034,736

360,180

402,518

1,797,434

1,516,499

360,180

384,062

744,242

629,979

1999

25,711,987

5,913,757

1,015,290

349,055

396,632

1,760,977

1,501,103

360,180

363,195

723,375

603,857

2000

26,022,202

7,025,995

1,016,418

343,564

393,530

1,753,512

1,480,706

343,564

353,210

696,774

591,197

2001

26,391,775

7,125,779

995,583

345,751

386,870

1,728,204

1,458,233

343,564

349,540

693,104

590,581

2002

26,785,043

7,365,887

983,997

336,122

376,585

1,696,704

1,442,967

343,564

349,264

692,828

581,132

2003

27,141,304

7,599,565

990,678

332,651

364,935

1,688,264

1,428,881

343,564

339,382

682,946

570,488

2004

27,498,648

8,524,581

1,014,090

335,567

358,767

1,708,424

1,464,093

335,567

336,889

672,456

571,442

2005

27,847,352

9,468,100

1,017,642

344,046

354,012

1,715,700

1,470,611

344,046

340,309

684,355

582,113

2006

28,205,075

9,589,726

1,050,273

345,449

351,268

1,746,990

1,500,959

345,449

348,535

693,984

589,557

2007

28,576,333

9,715,953

1,069,674

354,142

349,395

1,773,211

1,524,734

354,142

349,049

703,191

598,273

2008

28,961,242

9,846,822

1,090,365

360,775

352,902

1,804,042

1,551,853

360,775

358,244

719,019

611,445

Total

323,715,372

90,779,438

12,348,531

4,189,073

4,496,003

21,033,607

17,889,010

4,189,073

4,259,486

8,448,559

7,173,530

Indicated Population

DTaP=Diphtheria Tetanus and Acellular Pertussis Vaccine; MMR=Measles, Mumps, and Rubella Vaccine
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Doses
Administered

Indicated Population

were set to receive the doses. The final value found in the table takes into account the
coverage rate (Table 4.2).
4.3 Descriptive Analysis of Reports
There were 3245 AEFI reports submitted to the CAEFISS between 1997 -2008 (Table
4.4) for the conditions of interest. The distribution of reports varied over the years with
537 reports received in 1997 and only 214 reports received in 2006. There seems to be
no trend of a decline but on average remains steady between 200-300 reports per year.
There were 282 reports related to anaphylaxis, 130 for GBS, 575 for HHE, 201 for
thrombocytopenia, and 1794 for seizure related AEFI reports (Table 4.5). The greatest
number of reports came from nursing related health care professionals with 1454 reports;
there were also a large proportion of reports that were from unknown reporters with 1268
reports (Table 4.6).
4.4 Sensitivity of System
4.4.1 Overall Senstivity
The overall sensitivity for the various AEFI calculated varied greatly (Table 4.7). For
influenza the sensitivity was found to be 93.6% and 136.3% for GBS and anaphylaxis
respectively. For DTaP, sensitivity was found to be 15.0%, 1.0%, and 21.2% for
anaphylaxis, HHE, and seizures respectively, and for MMR the rates were 16.5%, 52.7%,
and 12.7% in relation to anaphylaxis, thrombocytopenia, and seizures respectively.
Sensitivity trends over the years were also analyzed and looked at specifically for each
AEFI and vaccine.
4.4.2 Influenza
Anaphylaxis related to influenza immunization fluctuated greatly between the years of
1997 and 2008 (Figure 4.2). The lowest rate was found in 2008 with 40.0% and was
found to be as high as 322.2% in 2004. Based on the figure it was obvious that there were
no general trends but rather a fluctuation in the yearly sensitivity related to anaphylaxis.
In analysis of GBS it was found to have a maximum sensitivity of 187.5% in 2003 and as
low as 20.0% in 1998.Both AEFI exhibited fluctuation year to year.
Table 4.4 Descriptive Statistics of Selected Reports from 1997-2008
4.4.3 DTaP
Anaphylaxis related to DTaP immunization fluctuated greatly between the years of 1997
and 2008. The highest rate was found in 2008 with 38.5% and was found to be as low as
0% in multiple years (1998, 2002, and 2003). In analysis of HHE it was
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Table 4.4 Descriptive Statistics of Selected Reports from 1997-2008

Year

Total Number
of Reports Filed

Number of Selected
Reports (N (%))

Total

46,407

3245

1997

4,806

537 (11.2)

1998

3,022

266 (8.8)

1999

2,956

208 (7.0)

2000

5,440

245 (4.5)

2001

5,297

239 (4.5)

2002

3,886

221 (5.7)

2003

3,302

220 (6.7)

2004

3,625

308 (8.5)

2005

5,831

273 (4.7)

2006

4,387

214 (4.9)

2007

3,855

286 (7.4)

2008 *

NA

228 (NA)

Notes: *Selected reports met criteria for selection based on AEFI filing. Total values not
available for 2008.
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Table 4.5 Number of Reports Received by CAEFISS between 1997-2008 Related to
Selected Adverse Events by AEFI
AEFI
Anaphylaxis
GBS
HHE
Thrombocytopenia
Seizures
Convulsions
Syncope
Fever

Number of
Reports (N)
282
130
575
201
1794
762
303
1055

Table 4.6 Number of Reports Received by CAEFISS between 1997-2008 Related to
Selected Adverse Events by Reporters’ Affiliation
Reporter’s Affiliation
Nursing
Physician
Pharmacist
IMPACT
Manufacturer
Other
Consumer
Unknown
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Number of
Reports (N)
1454
195
7
129
171
19
1
1268

Table 4.7 Total and Yearly Sensitivity by Vaccine and AEFI for 1997-2008
Influenza
Year
Overall
1997*
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
Mean

E
91
4
5
6
7
7
7
8
9
9
10
10
10

GBS
O
Sens
85 93.6%
2 50.0%
1 20.0%
6 100.0%
6 85.7%
6 85.7%
12 171.4%
15 187.5%
13 144.4%
4 44.4%
6 60.0%
6 60.0%
8 80.0%
90.8%

Anaphylaxis
E O
Sens
91 124 136.3%
4
5 125.0%
5
5 100.0%
6
6 100.0%
7 13 185.7%
7 13 185.7%
7 14 200.0%
8
5
62.5%
9 29 322.2%
9 10 111.1%
10 5
50.0%
10 15 150.0%
10 4
40.0%
136.0%

DTaP
Anaphylaxis
E O Sens
154 23 15.0%
13 1 7.7%
13 0 0.0%
13 1 7.7%
13 1 7.7%
13 2 15.4%
12 0 0.0%
12 0 0.0%
13 4 30.8%
13 4 30.8%
13 2 15.4%
13 4 30.8%
13 5 38.5%
15.4%
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HHE
E
O
35,778 350
3,097 175
3,033 38
3,002 24
2,961 33
2,916 38
2,886 37
2,858 33
2,928 36
2,941 36
3,002 18
3,049 35
3,104 22

Sens
1.0%
5.7%
1.3%
0.8%
1.1%
1.3%
1.3%
1.2%
1.2%
1.2%
0.6%
1.1%
0.7%
1.5%

Seizures
E
O
Sens
3,936 835 21.2%
341
45 13.2%
334
71 21.3%
330
49 14.8%
326
51 15.7%
321
55 17.1%
317
39 12.3%
314
47 15.0%
322
83 25.8%
324
74 22.9%
330
52 15.7%
335
64 19.1%
341
49 14.4%
17.6%

Table 4.7 Continued
MMR
Year
Overall
1997*
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
Mean

Anaphylaxis
E
O
Sens
103 17 16.5%
9
2
22.2%
9
0
0.0%
9
0
0.0%
9
0
0.0%
9
1
11.1%
8
0
0.0%
8
1
12.5%
8
3
37.5%
8
1
12.5%
8
1
12.5%
9
4
44.4%
9
4
44.4%
16.4%

Thrombocytopenia
E
O
Sens
239 126 52.7%
22
10 45.5%
21
7
33.3%
20
16 80.0%
20
16 80.0%
20
10 50.0%
19
8
42.1%
19
5
26.3%
19
10 52.6%
19
11 57.9%
20
11 55.0%
20
17 85.0%
20
6
30.0%
53.1%

E
7,174
653
630
604
591
591
581
570
571
582
590
598
611

Seizures
O
Sens
910 12.7%
127 19.4%
106 16.8%
74 12.3%
63 10.7%
58
9.8%
44
7.6%
47
8.2%
62 10.9%
72 12.4%
70 11.9%
85 14.2%
71 11.6%
12.1%

E=Expected; O=Observed; Sens=Sensitivity; DTaP=Diphtheria Tetanus and Acellular Pertussis Vaccine; MMR=Measles,
Mumps, and Rubella Vaccine; HHE=Hypotonic-Hyporesponsive Episode; GBS=Guillan-Barre Syndrome
Note: For DTaP Values for the year of 1997 were not included in the overall and the mean values due to the change from the
whole cellular to acellular pertussis in that year.
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GBS
Anaphylaxis

Figure 4.2 Sensitivity for Anaphylaxis and GBS Related to Influenza Immunizations
found to have a maximum sensitivity of 5.7% in 1997 and as low as 0.6% in 2006. There
was a stable level of reporting across time with little fluctuation of the sensitivity value.
Seizures had the highest sensitivity in 2004 with 25.8% and the lowest in 2002 with
12.3% (Figure 4.3).
4.4.4 MMR
Anaphylaxis related to MMR immunization fluctuated greatly between the years of 1997
and 2008 (Figure 4.4). The highest rate was found in 2008 with 44.4% and was found to
be as low as 0% in several years (1998-2000). In analysis of Thrombocytopenia it was
found to have a maximum sensitivity of 85% in 2007 and as low as 26.3% in 2003.
Seizures had the highest sensitivity in 1997 with 19.4% and the lowest in 2002 with
7.6%.
4.5 Sensitivity Analysis
A sensitivity analysis was conducted to assess the level of variation in the total sensitivity
of the system based on the variation in the expected event rate (+/- 5%) and total number
of administered doses (+/- 5%). A two-way analysis was also conducted using both
variations of the doses and +/-5% of the event rate to create four different permutations.
The difference from the primary model and the sensitivity analysis value was reported.
For DTaP anaphylaxis ranged from 10.5% to 11.6%, HHE ranged from 0.6% to 0.7%,
and seizures ranged from 8.9% to 10.3%.
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Figure 4.3 Sensitivity for anaphylaxis, HHE, and Seizures Related to DTaP
Immunizations

Figure 4.4 Sensitivity for Anaphylaxis, Thrombocytopenia, and Seizures Related to
MMR Immunizations
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For MMR, anaphylaxis ranged 12.0% to 14.0%. There was a greater total fluctuation
with the rarer AEFI such as anaphylaxis, GBS, and thrombocytopenia (Table 4.8).
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Table 4.8 One- and Two-way Sensitivity Analysis

Model Used

Influenza
Anaphylaxis
GBS
Sens
Δ
Sens
Δ

15.0%

136.3%

One-way
Expected Rate
"- 5%"

144.2%

7.9%

98.8%

5.2%

15.8%

0.8%

1.0%

0.1%

22.4%

1.2%

"+5%"

130.5%

-5.7%

89.5%

-4.2%

14.3%

-0.7%

0.9%

0.0%

20.2%

-1.0%

Administered Doses
"- 5%"
"+5%"

144.2%
130.5%

7.9%
-5.7%

98.8%
89.5%

5.2%
-4.2%

15.8%
14.3%

0.8%
-0.7%

1.0%
0.9%

0.1%
0.0%

22.4%
20.2%

1.2%
-1.0%

151.2% 15.0%
136.3% 0.0%
124.0% -12.3%
136.3% 0.0%

103.7%
93.4%
85.0%
93.4%

10.0%
-0.2%
-8.6%
-0.2%

16.5%
15.0%
13.5%
15.0%

1.6%
0.1%
-1.4%
0.1%

1.1% 0.1%
1.0% 0.0%
0.9% -0.1%
1.0% 0.0%

23.5%
21.3%
19.2%
21.3%

2.3%
0.1%
-2.0%
0.1%
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1.0%

Seizures
Sens
Δ

Primary

Two-way
Expected Administered
Rate
Doses
"-5%"
"-5%"
"-5%"
"+5%"
"+5%"
"+5%"
"+5%"
"-5%"

93.6%

Anaphylaxis
Sens
Δ

DTaP
HHE
Sens
Δ

21.2%

Table 4.8 Continued
Anaphylaxis
Sens
Δ
16.5%

MMR
Thrombocytopenia
Sens
Δ
52.7%

Seizures
Sens
Δ
12.7%

17.3%
15.7%

0.9%
-0.7%

55.5%
50.2%

2.8%
-2.5%

13.4%
12.1%

0.7%
-0.6%

17.3%
15.7%

0.9%
-0.7%

55.5%
50.2%

2.8%
-2.5%

13.4%
12.1%

0.7%
-0.6%

Two-way
Expected
Administered
Rate
Doses
"-5%"
"-5%"
18.3%

1.8%

58.3%

5.6%

14.1%

1.4%

0.0%
-1.5%
0.0%

52.7%
47.7%
52.7%

0.0%
-5.0%
0.0%

12.7%
11.5%
12.7%

0.0%
-1.2%
0.0%

Model Used
Primary
One-way
Expected Rate
"- 5%"
"+5%"
Administered Doses
"- 5%"
"+5%"

"-5%"
"+5%"
"+5%"

"+5%"
"+5%"
"-5%"

16.5%
14.9%
16.5%

Sens=Sensitivity, Δ=Difference between Primary model and sensitivity analysis value; DTaP=Diphtheria Tetanus and
Acellular Pertussis Vaccine; MMR=Measles, Mumps, and Rubella Vaccine; HHE=Hypotonic-Hyporesponsive Episode;
GBS=Guillan-Barre Syndrome
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CHAPTER 5. DISCUSSION
5.1 Overview of Findings
This is the first study to assess the sensitivity of the CAEFISS. Sensitivity varied by
vaccines and within vaccines specific AEFI, from 1997 to 2008. The overall sensitivity
varied by selected AEFI from 1.0% to 136.3%. The greatest variations were found in
anaphylaxis which was analyzed in all three of the vaccines examined. Variations in
sensitivity were found between vaccines, AEFI within the same vaccine and over within
and among vaccines. There was evidence that age group, timing of event, and rarity also
affected sensitivity within vaccines.
5.1.1 Comparison to Past Literature
As discussed in Chapter 2, the only major study to look at the assessment of sensitivity of
a vaccine AEFI surveillance system was that of Rosenthal et al. (1995). This study had
four similar AEFI that overlapped with those in the paper by Rosenthal et al. (1995):
seizures associated with DTaP and MMR, HHE with DTaP, and thrombocytopenia with
MMR.
In comparing thrombocytopenia associated with MMR, the sensitivity was less than one
percent in the study by Rosenthal et al. (1995) and 52.7% in the present study. This
difference may be explained in large part by the introduction of the IMPACT program
and its specific targeting of thrombocytopenia through the use of the active surveillance
system (Jadavji, Scheifele, & Halperin 2003).
Sensitivity for seizures related to DTaP was higher in the study by Rosenthal et al. (1995)
than in the present study. Rosenthal et al. (1995) found sensitivity values of 24% versus
17.6% in this study. While these differences are significant, note that a whole-cell
pertussis vaccine known to be associated with a higher expected rate of seizures was used
during the time period that Rosenthal analyzed. The vaccine used during the course of
this study is acellular with a lower of incidence of seizure as discussed previously. This
risk of seizures was of a greater concern to clinicians during that time period than during
the period studied here, so it was more likely that clinicians would report its appearance.
This has become less of a concern as a result of the formulation change, a downward
trend of reporting by clinicians and the public was expected. The present study excluded
any reports related to the whole-cell pertussis vaccines, and for the overall value
calculation, all data from 1997 were excluded to ensure that this transition year did not
affect the sensitivity.
Sensitivity for seizures related to MMR was also higher in the study by Rosenthal et al.
(1995) than in the present study. Rosenthal and his colleagues found sensitivity values of
27% versus 12.1% in this current study. This may be related to the correlation between
DTaP and MMR. As discussed above, the concern of clinicians at the time of the
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Rosenthal study for seizures was much higher than recent years.MMR and DTaP
administration are closely related and often administered at similar visits. There were a
large proportion of reports of seizures in this study in which both DTaP and MMR were
both reported to have been administered.
This study also found lower sensitivity associated with HHE (approximately 4% versus
1.0% in our study). This difference may be associated with a general downward trend in
reporting. This was expected, because as a vaccine is used more often, clinicians become
more acclimated to its use and associated AEFI leading to fewer reports.
Although the results varied, Rosenthal and colleagues made similar conclusions with
what specific factors affected sensitivity, such as clinical seriousness, temporal
proximity, and healthcare awareness. These findings paralleled this study’s finding that
sensitivity was affected by both temporal proximity and expected rates of occurrence.
The differences of results may be due to variations in the systems and timing of the
studies. The time period in which their analysis was conducted (1985-1990) differed from
that in this study (1997-2008).
5.1.2 Results by Vaccines
5.1.2.1 AEFI Related to Influenza Vaccination
In the present study, influenza vaccination was used as an indicator of all adult
immunizations. Estimates of sensitivity for influenza vaccine–associated reporting of
anaphylaxis and GBS were limited to those aged 12 years and older. The highest adult
sensitivities were for GBS and anaphylaxis (136.3% and 93.6%, respectively). It was
evident that the immunization of adults with influenza vaccine had the highest sensitivity
in the study.
Sensitivity of both GBS and anaphylaxis related to influenza vaccination were highly
unstable when analyzed on a yearly basis. This variation may be due to the rarity of the
events. This rarity led to a small number of expected events which made small variations
in the actual data appear more significant than they truly were in the overall sensitivity.
This could be even more pronounced when other factors within the population impact the
occurrence of an AEFI. One example of this confounding is the occurrence of GBS due
to an outbreak of Campylobacter.
Other factors such as the rate of occurrence and the assumption that all cases are true
cases could also impact these rare adverse events. Rare events have an increased
likelihood of being misreported because reporters may be less experienced with a rare
AEFI. This lack of experience may also increase the likelihood of misreporting and
misdiagnosing adverse events, leading to inconsistency in reporting. This inconsistency is
even more pronounced without case-definitions. Without the assistance of case
definitions the literature has shown clinicians’ case determinations are inconsistent (Kohl
et al. 2008). Inconsistency in reporting may be one of the major causes of greater
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variation in reporting, and this effect would be much more pronounced for adverse events
with low rates of occurrence.
5.1.2.2 AEFI Related to DTaP Vaccination
Estimates of sensitivity for DTaP related AEFI were completed for anaphylaxis, HHE,
and seizures. The overall sensitivity was found to be 15.0% for anaphylaxis, 1.0% for
thrombocytopenia, and 21.2% for seizures.
Seizures had the highest sensitivity of the three AEFI related to DTaP. The higher
reporting of seizures maybe due to the past experience with the whole-cell pertussis
vaccine, which was changed to the acellular formulation due to concerns with the rate of
seizures related to vaccination. Although the rate of occurrence of the AEFI was
decreased, this may still be an area of concern for clinicians. Seizures are also a relatively
more common adverse event and displayed a steady sensitivity over time.
HHE was the most common of the three AEFI and exhibited the lowest sensitivity. HHE
was the most stable sensitivity of all the AEFI in the study and within DTaP related
AEFI. This is most likely due to HHE having the highest rate of occurrence for DTaP
AEFI and AEFI in the study as a whole. Sensitivity for HHE and seizures were stable
over the years.
Anaphylaxis related to DTaP vaccination was not the highest sensitivity within DTaP.
This varies from the other two vaccines looked at in the study, in which anaphylaxis was
the highest of the AEFI within vaccines. The results of anaphylaxis within DTaP did
parallel those in the other vaccines in terms of year to year sensitivity, which was found
to vary greatly.
5.1.2.3 AEFI Related to MMR Vaccination
Estimates of sensitivity for MMR related AEFI were completed for anaphylaxis,
thrombocytopenia, and seizures. The overall sensitivity was found to be 16.5% for
anaphylaxis, 52.7% for thrombocytopenia, and 12.7% for seizures.
Thrombocytopenia was found to have the highest sensitivity of the three AEFI related to
MMR. This may be explained by the IMPACT program and its specific targeting of
thrombocytopenia through the use of the active surveillance system (Jadavji et al. 2003).
It may be difficult to determine how much of this is due to the IMPACT program. Only
33 out of the 239 thrombocytopenia reports were coded as IMPACT, some reports may
be related to the program and labeled as reports from nurses or physicians.
Seizures were the most common of the three AEFI and exhibited the lowest sensitivity.
Sensitivity for seizures was stable over the years when compared to thrombocytopenia
and anaphylaxis. This variation of anaphylaxis and thrombocytopenia may be due to the
rarity of the events.
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5.1.3 Adult versus Pediatric Reporting
In the present study, influenza vaccination was used as an indicator of adult
immunizations. DTaP and MMR were predominantly used as indicators of immunization
in the pediatric population. Estimates of sensitivity for influenza vaccine–associated
reporting of anaphylaxis and GBS were limited to those aged 12 years and older, whereas
DTaP and MMR sensitivity were limited to preschool-aged populations to the age of 8
years. The highest adult sensitivities were for GBS and anaphylaxis. There was evidence
that the immunization of adults with influenza vaccine had a higher sensitivity. It is
important to note that the AEFI selected for influenza were both rare and this may limit
the ability to conclude that adult sensitivity was higher than that of the pediatric
population.
This differentiation of adult immunization and pediatric immunization may be attributed
to factors pertaining to the individual responsible for reporting and administering the
vaccines (Duclos, Hockin, Pless, & Lawlor 1997). Further research would be required to
help better understand these findings.
5.1.4 Common versus Rare Adverse Events
The AEFI considered within this study varied in rate of occurrence with some being more
common than others. As discussed in the Methods chapter, these vaccines were selected
on the basis of the variation in their expected rates of occurrence in order to compare
more common AEFI with rarer AEFI (Table 5.1). The event with the highest expected
rate of occurrence was HHE associated with DTaP. This adverse event was also
associated with the lowest overall sensitivity rate in this study. Seizures with both MMR
and DTaP had lower sensitivity of 12.7% and 21.2%, respectively. They were the 2nd and
3rd lowest sensitivity values found. In contrast, the three most common adverse events
were among the lowest sensitivity values of the study and exhibited the greatest stability
from year to year.
AEFI that have higher rates of occurrence appear to have a lower sensitivity and more
stable sensitivity over time. As an AEFI becomes more common, it will be more
frequently seen by those administering the vaccine, and its sensitivity may decrease and
the stability of reporting may increase. Rarer events have a greater likelihood that they
will be misdiagnosed than more common events. This misdiagnosis may be due to a lack
of familiarity with the event because of its rarity.
As discussed above, inconsistencies in reporting may also affect the stability of
sensitivity over time and are more pronounced in rare adverse events. Rare AEFI may
also be more greatly affected by smaller variations in their actual occurrence. A greater
number of reports would be needed to vary the sensitivity of a common AEFI with a
higher rate of occurrence. Rarer adverse events had the greatest variations when estimates
were changed in the model.
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Table 5.1 Ordered Expected Occurrence per Million Doses from Lowest to Highest

Order

Adverse Event
(Vaccine)

Rate of
Occurrence
per Million
Doses

1

HHE (DTaP)

14000

1.0%

1.5%

2

Seizures (MMR)

1000

12.7%

12.1%

3

Seizures (DTaP)

220

21.2%

17.6%

33

52.7%

53.1%

14

16.5%

16.4%

9

15.0%

15.4%

1

93.6%

136.0%

1

136.3%

90.8%

4
5
6
7
8

Thrombocytopenia
(MMR)
Anaphylaxis
(MMR)
Anaphylaxis
(DTaP)
Anaphylaxis
(Influenza)
GBS (Influenza)

Overall
Sensitivity

Average Sensitivity
Sensitivity
Range
0.6%1.3%
7.6%19.4%
12.3%25.8%
26.3%85.0%
0.0%44.4%
0.0%38,5%
40.0%322.2%
20.0%187.5%

5.1.5 Timing of AEFI Onset
For all three of the vaccines analyzed, the most acute AEFI assessed was anaphylaxis, a
serious systemic reaction that sometimes occurs in response to any vaccine and
commonly occurs within minutes to hours after administration (Coop et al. 2008;
Erlewyn-Lajeunesse, Bonhoeffer, Ruggeberg, & Heath 2007; Kagy & Blaiss 1998).
Anaphylaxis related to influenza vaccination was found to have the highest sensitivity in
the study, with an overall sensitivity of 136.6%. This value was the only value in the
study that was found to be above 100%, meaning that there was more reporting than
expected. This high sensitivity may, in part, be due to over-reporting or a misdiagnosis of
the adverse event.
AEFI with slower onsets of days to weeks had lower sensitivities. GBS related to
influenza vaccination, seizures related to MMR vaccination, and HHE related to DTaP
were the selected to represent AEFI that have a longer duration of onset post
immunizations. These AEFI were also the lowest sensitivities in their respective
vaccines. This may show that when an AEFI is temporally separated from the
administration of the vaccine, it is less likely to be reported. This may be due to the more
difficult task of finding correlation to the vaccine days or weeks after its administration,
as compared to minutes and hours after its administration.
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In addition to being temporally acute, anaphylaxis is also a rare AEFI as discussed
previously. Examination of trends over years for all three vaccines showed that
anaphylaxis was present with the greatest variations over time. Thus, not only does the
temporal acuity of an adverse event seem to increase the reporting, but it also may be a
factor in determining the instability of reporting over time. This may also be clouded by
the general rarity of anaphylaxis.
5.1.6 Sensitivity Analysis
A sensitivity analysis of this study was conducted to assess the level of variation in the
overall sensitivity. One-way and two-way analyses were conducted for the two major
values in the model: the expected rate and the number of administered doses. The greatest
variation was seen with the rare adverse events. GBS and anaphylaxis related to influenza
vaccination had a variation of 10.0% and 15.0%, respectively. The most common adverse
events such as HHE and seizures related to DTaP had variations of 0.1% and 2.3%,
respectively. This can be attributed to the fact that a single additional case can cause great
variation in the calculated sensitivity of rare adverse events, compared to the more
common adverse events. The results from the sensitivity analysis can be used to better
determine how much credence to lend to these results. It can be assumed that the specific
findings of the more common adverse events are more robust. In contrast, those rare
adverse events need greater scrutiny and more complex analysis when large changes in
sensitivity occur. This adds increased importance for the need to standardize reporting
through standard case definitions, in order to stabilize the sensitivity. Therefore when
large variations in reports occur, there can be a quicker response to the number of reports,
rather than a need for further assessment into the PPV of the reports. Reporters will be
diligent in reporting cases that meet a level of diagnostic certainty as comfort with casedefinitions increases.
5.2 Limitations
5.2.1 Expected Rates of AEFI
Expected rates had to be estimated based on previous clinical trials and epidemiological
studies, which may not produce perfect expected rates. In order to address this study
limitation, a thorough systematic search was conducted using multiple sources. In
situations where multiple values were found, the best designed studies were used as the
primary value. Additionally, to ensure that values were robust, a sensitivity analysis of
this study was utilized to assess how greatly the variation in the expected rates would
affect the results. The variation in the expected rate affected the rarer adverse events to a
great degree, as discussed previously. The greatest fluctuation was seen in anaphylaxis
associated with influenza vaccination. It varied from 124.0% to 151.2%. In more
common adverse events such as HHE, the variation due to these estimates was far less
pronounced, varying by only 0.1%.
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5.2.2 Coverage Rates
Coverage rates were used in the model to compute the expected number of administered
doses. As discussed in past chapters, these values as discussed in past chapters were
drawn from survey data. In some of the cases of DTaP, MMR, and influenza the surveys
were not conducted yearly. In years where there were no surveys completed, an
extrapolation of the past and future coverage rates was used, assuming a linear growth.
This assumption may not be valid as there may be unknown but important factors
affecting the coverage rate. This may not be as distinct in DTaP and MMR vaccinations
since their rates for all the doses held within 1-2% of each other throughout the time
period. The greatest impact this may have is in the influenza vaccination which had a
great increase in rate over the time period analyzed. To ensure that our estimations were
not unrealistic a double check was conducted using the number of influenza doses
distributed nationally. Dose distribution data were provided by PHAC who received the
data from the manufacturers. It was found that estimates for doses administered were
reasonably close to these values (Table 5.2). The estimates never exceeded the number of
doses distributed. To also insure that estimates did not highly impact the final values as a
part of the sensitivity analysis conducted all coverage rates were adjusted by +/-5% for
both the one-way analysis and two-way analysis. It was found that this adjustment had
the greatest impact on the rarer adverse events similar to the results found with the
expected rates.
Table 5.2 Comparison of Estimated Influenza Vaccine Doses Administered to Reported
Doses Distributed
Year
Overall
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008

Estimated Doses
Administered
90,779,438
3,771,992
4,831,281
5,913,757
7,025,995
7,125,779
7,365,887
7,599,565
8,524,581
9,468,100
9,589,726
9,715,953
9,846,822

Doses Distributed
115,824,359
5,249,999
5,062,361
5,750,237
12,199,380
9,330,555
10,477,216
11,080,935
11,309,614
11,494,459
11,893,503
11,443,640
10,532,460

Note: These numbers are for total doses of all types of influenza vaccine marketed in
Canada

38

5.2.3 Issues with Spontaneous Systems
One Typical key limitation in the use of spontaneous reporting system data is missing and
incomplete reports. This inconsistency in data makes it difficult to analyze many of the
reports since they may not contain all the necessary data. This limitation does not impact
our study, because the information was limited to age of patient, year of report, vaccines
administered, and type of adverse event which are almost always present within a report.
Another limitation with reports associated with spontaneous systems is the PPV of the
reports and how this may affect the sensitivity. Two factors can affect whether a report
represents a true adverse event causally related to the vaccine. The first factor is that of
the factuality of the report. In other words, is the report of a specific AEFI truly related to
that AEFI, or is it a misdiagnosis? For anaphylaxis this is especially problematic since
rapid institution of treatment can alter an evolving event and make it impossible to
determine, after the fact, whether it in fact meets the definition of anaphylaxis. This issue
can be less problematic for other AEFI such as thrombocytopenia. The second issue
relates to causality. Not all reports received represent causally associated adverse events
because temporal association does not prove casual association. For example, background
disease occurrence in the population may have caused an event to occur but still may be
reported as an AEFI. This may be evident with such AEFI as GBS and
thrombocytopenia. Both of these issues may lead to excess reporting and be the cause of
higher than expected sensitivity and maybe much more pronounced in rare AEFI. In past
studies of vaccine adverse event reporting systems, some of the reports were eliminated
based on timing of the adverse events in correlation with vaccination. In this study no
reports were eliminated because of the belief that that inclusion of those reports is helpful
in assessing the extent of reporting.
5.3 Implications
This study is the first of its kind for the Canadian system. Further research and utilization
of the data are necessary. Despite the inherent limitations of spontaneous systems, it is
important to strive for a highly standardized system with regular measurement of
characteristics like sensitivity to understand to what degree variation exists. A continuous
and annual evaluation of the quality of the system is important for the purpose of
improvement and may help strengthen public confidence. Spontaneous systems are not
rigid in nature but rather are fluid entities, so annual assessment would be essential to any
successful system. Current guidelines recommend annual assessment of sensitivity and
other characteristics in order to make proper adjustments to the system that may result in
increased and higher quality reporting (German 2001). Sensitivity as an assessment tool
of the system holds special importance since the model to create it takes into account
changes in population, coverage, and administration. This value is more useful in
assessing the system than simply looking at the number of reports annually. VAERS
currently conducts this type of assessment annually as a retrospective assessment of the
system.
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The systems are dependent on outside reporters, so perception of those outside the system
is relevant (Wysowski & Swartz 2005). A better understanding of the system will not
only raise further research questions but also will serve as a tool for hypothesis
generation and quality improvement initiatives. To improve public confidence
publication of these results and other results utilizing the reports must be published. This
will improve public confidence for a few reasons. 1) The results will make evident to the
public that their reports are being utilized. 2) The publication of these results will
increase public confidence that the system receives a substantial number of reports, even
for rare adverse events, at a level that is high enough to maintain the systems primary
goal. 3) The system exhibits ability for response to increased reports. 4) Further efforts to
improve the system are continually being made. 5) Future research will continue to better
understand reporting and possibly look at greater applications and assessment of the
reports.
The results show that although the overall sensitivity for each AEFI was quite variable,
the system had sensitivities that were as high as seen in past research. Year by year
analysis showed steady rates in more common adverse events and greater variation in
more rare events. This variation over time gives greater evidence for the need of
implementation of standardized case-definitions to be used in reporting. Further
education of those administering vaccines coupled with incorporation of the case
definitions into the reporting forms may prove to be beneficial in assisting to stabilize the
fluctuation of sensitivity. This was especially apparent in the reporting of anaphylaxis,
which is commonly misdiagnosed and misreported. Implementation of such casedefinitions may prove to improve specificity and PPV, and help limit variation of
sensitivity overtime.
Implementation of case-definitions has been at the forefront of current international
vaccine safety initiatives. The Brighton Collaboration is an international collaboration
aiming to help evaluate issues related to vaccine safety. One of the major goals of the
collaboration was to standardize case definitions that can be used internationally.
Standardization of these case definitions would help comparability of research and help
in monitoring reporting (Ball et al. 2002; Bonhoeffer et al. 2002; Kohl et al. 2007). The
case-definitions as well as published studies utilizing the case-definitions are accessible
online to the public. However, integration of these case definitions into the reporting
forms is only now beginning.
There are published papers discussing the Brighton collaboration. The majority of the
published papers has been on the discussion of the creation and need for case definitions.
The case-definitions may help in data comparability in clinical trials, surveillance
systems, and retrospective epidemiological studies (Clark & Camargo 2007). It is
important to note that the case-definitions are not meant to be used for the identification
of a causal assessment or establishing possible management for the adverse event.
Rather, they are meant to help define various levels of diagnostic certainty based on the
current literature using specified criteria unique to the adverse event. The case definitions
are placed at three different levels of evidence with different diagnostic criteria being
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placed in one of the three levels. These levels are used to then assess the likelihood of a
causal association.
Research is also ongoing on the use and applications of these case-definitions. One
published paper looked at assessing the applicability, reliability, sensitivity and
specificity of applying the case definitions to the VAERS data (Kohl et al. 2008). The
study used the case definitions for fever, generalized convulsive seizures, HHE,
intussusceptions, nodule at injection site, and persistent crying. The study concluded that
the use of the case definitions had high sensitivity and specificity when compared to
clinician review of the case reports. The study confirms the importance of these casedefinitions and the need for continued development and acceptance in vaccine safety
surveillance systems globally. Currently, the CAEFISS has begun plans and various
projects on the implementation and utilization of these case-definitions in relation to
anaphylaxis. The findings of this study strengthen the importance of this initiative.
5.4 Future Research
5.4.1 PPV Analysis
Although this is an assessment of surveillance systems, this study, along with previous
research, suggests further value and benefit in the assessment of the PPV of a system as
well (German 2000). Assessment of the PPV analysis will enable the researchers to better
understand the quality and the types of reports being received. In this assessment of
sensitivity, it is assumed that the PPV is 100%, in other words, all reports received are
true reports as well as casually associated. In reality, this may not hold true and many
reports may be erroneous and need to be assessed on a report by report basis. A high PPV
refers to a system in which a large proportion of reports received are true positives,
versus a low PPV which is evidence of a system receiving many false positive reports. A
low PPV may be a sign of wasted resources and the need for the implementation of
education and stricter case-definitions for reporters.
Currently, Canada is in the pilot phase of applying many of these case-definitions to its
systems. Applications of these case-definitions and studies on how they affect both the
sensitivity and the PPV would be of importance. As evidenced by the results in this
study, especially with anaphylaxis, there may be over-reporting. The implementation of
case-definitions and education concerning these adverse events may help stabilize the
variation in reporting many of the adverse events.
5.4.2 Policy and Reporter Assessment
The impact that other factors may have on the sensitivity of the reporting system is also
of interest. In our current study, we assessed the specific characteristics of the AEFI
itself, such as vaccine, rate of occurrence, age of patient, and timing of adverse event.
Reporting may also be impacted by factors associated with the reporters, such as
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professional affiliation. The impact of professional affiliation on reporting is tied closely
with the type of policy in various provinces. In some provinces the majority of
vaccination is completed by public health officials rather than nurses and physicians in
practice settings. Policy impacts the mandates around reporting. The policies of some
provinces make adverse event reporting mandatory, while it is voluntary in others. It is
unknown whether these policy variations impact the reporting system and how they
would impact the sensitivity of the system.
5.4.3 Trending Analysis Using Moving Averages
The results of this study showed evidence of variation in the year by year analysis. It was
difficult to ascertain which factors and which years were of importance; this was
especially true in rarer AEFI. The methodology of moving averages has been used in
business and disease outbreak research. A moving average is a form of average which has
been adjusted to allow for seasonal or cyclical components of a time series. Moving
average smoothing is a smoothing technique used to make the long term trends of a time
series clearer.
The application of the moving average for vaccine safety has not been reported in the
literature. Small studies have attempted to apply the methodology to adverse event
reporting within hospitals (Morton 2009). The application of such a methodology would
allow for assessment of trending as well as a potential for signaling that maybe more
apparent. The application of this methodology to adverse event reporting is still in its
infancy and has not been applied to sensitivity. In application to a rare event such as GBS
related to influenza vaccinations (Figure 5.1), we see that this methodology limits the
variation and depicts a smoother curve.
5.5 Conclusion
This is the first assessment of the sensitivity of the CAEFISS, and this study found that
the system has reasonable ability to detect AEFI on a national level. This study found that
the overall sensitivity of the CAEFISS varied from 1.0% to 136.6% for various adverse
events for the years 1997-2008. CAEFISS had comparable sensitivity to previously
completed studies. Many of the AEFI had sensitivity values higher than the 5%-10%
range traditionally seen in other passive surveillance systems related to adverse events
(Begaud, Martin, Haramburu, & Moore 2002). The greatest variation of sensitivity was
seen between vaccines. Rarity and timing of the AEFI also appeared to have an impact on
the sensitivity. Variation of sensitivity and the variation found in the sensitivity analysis
lend credence to the further development and implementations of case definitions for
rarer adverse events, especially anaphylaxis. This type of analysis should be conducted
annually for continued assessment of the system. Further research of other factors that
impact reporting is necessary.
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Figure 5.1 Application of Moving Averages to GBS Related to Influenza Vaccination; 1-,
3-, and 5- Year Moving Averages
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